About this trial
This is a multicentric retrospective observational cohort study.
As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene.
As secondary objectives, this study aims:
* To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome * To identify the predictors of complete renal remission of nephrotic syndrome * To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease * To assess the adverse events of corticosteroids in patients treated with corticosteroids.
Eligibility criteria
Qualifiers
Adult patients followed in 6 nephrology centers between 01/01/2016 and 01/06/2024.
With characterization of APOL1 gene risk status
Proteinuria/creatinuria ratio > 3 g/g at diagnosis of renal disease (within 48 hours of the diagnostic renal biopsy)
Hypoalbuminemia < 30 g/L at diagnosis of renal disease (within 48 h of diagnostic renal biopsy)
Disqualifiers
Presence of diffuse deposits of immunoglobulins or complement fractions on immunofluorescence study
Presence of endo- or extracapillary hypercellular lesions on light microscopy
Opposition to the use of medical data
Trial design
Treatments tested in this trial
- Not listed